| Literature DB >> 19445015 |
Yukie Yoshii1, Takako Furukawa, Hiroshi Yoshii, Tetsuya Mori, Yasushi Kiyono, Atsuo Waki, Masato Kobayashi, Tetsuya Tsujikawa, Takashi Kudo, Hidehiko Okazawa, Yoshiharu Yonekura, Yasuhisa Fujibayashi.
Abstract
Understanding tumor-specific metabolism under hypoxia is important to find novel targets for antitumor drug design. Here we found that tumor cells expressed higher levels of cytosolic acetyl-CoA synthetase (ACSS2) under hypoxia than normoxia. Knockdown of ACSS2 by RNA interference (RNAi) in tumor cells enhanced tumor cell death under long-term hypoxia in vitro. Our data also demonstrated that the ACSS2 suppression slowed tumor growth in vivo. These findings showed that ACSS2 plays a significant role in tumor cell survival under hypoxia and that ACSS2 would be a potential target for tumor treatment. Furthermore, we found that tumor cells excreted acetate and the quantity increased under hypoxia: the pattern of acetate excretion followed the expression pattern of ACSS2. Additionally, the ACSS2 knockdown led to a corresponding reduction in the acetate excretion in tumor cells. These results mean that ACSS2 can conduct the reverse reaction from acetyl-CoA to acetate in tumor cells, which indicates that ACSS2 is a bi-directional enzyme in tumor cells and that ACSS2 might play a buffering role in tumor acetyl-CoA/acetate metabolism.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19445015 DOI: 10.1111/j.1349-7006.2009.01099.x
Source DB: PubMed Journal: Cancer Sci ISSN: 1347-9032 Impact factor: 6.716